All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Avacopan
Therapeutic Area: Immunology Product Name: CCX168
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: ChemoCentryx
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2020
Details:
ChemoCentryx plans to discuss the results with the U.S. Food and Drug Administration as it has obtained evidence of avacopan’s ability to improve renal function, being well-tolerated in C3G patients to date.